Background Secukinumab is a fully human antibody that neutralizes interleukin-17A. It has significant efficacy and a favourable safety profile in moderate-tosevere plaque psoriasis and psoriatic arthritis. Objectives To compare secukinumab with fumaric acid esters (FAEs) in a randomized controlled trial. Methods In this 24-week, randomized, open-label, multicentre study with blinded assessment, patients with moderate-to-severe plaque psoriasis, naive to systemic treatments, were randomized to receive secukinumab 300 mg subcutaneously or oral FAEs. The primary end point was ≥ 75% improvement from baseline Psoriasis Area and Severity Index score (PASI 75 response) at week 24, and missing patients were considered responders if they were responders at the time of dropout. Results In total 202 patients were randomized and 200 were treated with at least one dose. Outcomes at week 24 were available for 147 and imputed for 53 patients. Discontinuations were mostly due to adverse events, which occurred more frequently in the FAE group (1Á9% vs. 33Á0%). At week 24, significantly more patients receiving secukinumab compared with FAEs achieved PASI 75 response (89Á5% vs. 33Á7%, P < 0Á001), PASI 90 response (81Á0% vs. 28Á4%, P < 0Á001) and Dermatology Life Quality Index 0 or 1 response (71Á4% vs. 25Á3%, P < 0Á001). Conclusions Secukinumab demonstrated superior efficacy to FAEs in patients with psoriasis over a 24-week period.
What does this study add?
• This head-to-head study showed that secukinumab has significantly greater efficacy in patients with psoriasis in terms of achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) response at week 24.
• PASI 50, 90 and 100 responses were all higher for secukinumab vs. FAEs at week 24.
• Secukinumab showed a favourable safety profile, and fewer patients discontinued secukinumab due to adverse events compared with patients on FAEs.
Despite limited evidence, fumaric acid esters (FAEs) have been used in the treatment of psoriasis in Germany and the Netherlands for many years. 1, 2 FAEs are among the conventional systemic treatments recommended by the 'European S3-Guidelines on the Systemic Treatment of Psoriasis Vulgaris', to be used as a first-line treatment prior to biological treatments. 3 Currently, the only registered FAE in Germany is Fumaderm â , a mixture of the main ingredient dimethylfumarate and three salts of ethylhydrogenfumarate. 4 In line with their approved therapeutic indications at the time of the European S3-Guidelines update in 2015, most biological treatments have been recommended in the second-line treatment of psoriasis vulgaris. 3 Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin-17A, has been shown to have significant efficacy in the treatment of moderate-to-severe psoriasis and psoriatic arthritis, with a favourable safety profile. 5, 6 In Europe, secukinumab was the first biological treatment to be approved for the firstline treatment of moderate-to-severe plaque psoriasis . 7 FAEs are licensed for the treatment of moderate-to-severe psoriasis in Germany but are used off-label in other countries. 8 FAEs have demonstrated benefit compared with placebo in a number of randomized controlled trials. 8 For evidence-based decisions on the use and value of first-line treatment options such as secukinumab and FAEs, direct head-to-head comparisons are mandatory. In the PRIME study (NCT02474082), we sought to compare secukinumab with FAEs in patients who were naive to prior systemic treatments. The study was initiated due to, and designed in accordance with, health technology assessment requirements in Germany.
Patients and methods

Study design
This 24-week, randomized, open-label, active-comparator, parallel-group, superiority study was conducted in accordance with the ethical principles of the Declaration of Helsinki at 33 sites in Germany. The study was initiated in April 2015 (first patient, first visit), with the last patient's last visit in June 2016. All investigators and institutions obtained approval or favourable opinion from the appropriate institutional review board, independent ethics committee and health authority for the trial protocol.
Randomization and blinding
Eligible patients were randomized 1 : 1 to receive subcutaneous injections of secukinumab 300 mg or oral FAEs per label, via an automated randomization list. Randomization numbers were assigned to patients by the investigators in consecutive order, who then assigned the treatment displayed on the card. Randomization lists and sealed envelopes were generated by personnel who were not otherwise involved in the trial. The blinded assessor and all involved personnel were instructed to desist from any discussions regarding safety, efficacy and treatment allocation of the study and patients in the presence of the blinded assessor. Efficacy parameters were assessed by blinded assessors who were not involved in any other study procedures and who did not have access to the allocation data or case report forms.
Patient selection
Eligible patients (age ≥ 18 years) had moderate-to-severe plaque psoriasis defined by a Psoriasis Area and Severity Index (PASI) > 10, an affected body surface area (BSA) > 10% and a Dermatology Life Quality Index (DLQI) > 10 at baseline. Psoriasis had been diagnosed at least 6 months before randomization and patients had documented insufficient responses to topical psoriasis treatment alone. Key exclusion criteria were any previous biological or conventional systemic treatment including psoralen with ultraviolet, known contraindications to systemic treatments at baseline, and ongoing use of prohibited concomitant treatments including psoriasis treatments with pharmacologically active ingredients. Prior nonsystemic phototherapy, for example ultraviolet A (UVA) and UVB, was permitted, if not combined with psoralen derivatives. All patients provided written informed consent before commencing the study.
Study treatments
The FAE dose was titrated according to the local product information (Fumaderm; Biogen Idec, Cambridge, MA, U.S.A.) in weekly steps with low-dose gastroresistant FAE tablets administered daily (morning, noon and evening) at 0-0-1 (i.e. one tablet in the evening only; week 0), 1-0-1 (week 1) and 1-1-1 (week 2) until a 40-tablet blister was consumed. High-dose gastroresistant FAE tablets were administered 0-0-1 starting on the last day of week 2 and continuing through week 3, then 1-0-1 (week 4), 1-1-1 (week 5), 1-1-2 (week 6), 2-1-2 (week 7) and 2-2-2 (weeks 8-24). The exact FAE dosing schedule is outlined in Appendix S1 (see Supporting Information). Secukinumab 300 mg was administered as two subcutaneous injections of 150 mg in a SensoReady pen at weeks 0, 1, 2 and 3, then every 4 weeks from week 4 to week 20.
Study objectives
The primary objective was to demonstrate the superiority of secukinumab over FAEs based on the proportion of responders achieving ≥ 75% improvement in PASI (PASI 75) at week 24. Safety and tolerability were evaluated by adverse events (AEs), laboratory and vital sign assessments, and physical examinations. AEs were coded using the Medical Dictionary for Regulatory Activities version 19Á0 terminology.
The study protocol was amended twice after the study had commenced, after 6% and 100% of the patients had been randomized, respectively, to implement additional safety measures. Key changes were to allow inclusion and study continuation despite laboratory value deviations of serum creatinine and haematology, providing they were not deemed clinically relevant by the investigator.
Statistical analysis
Efficacy end points were assessed for the full analysis set, consisting of all randomized patients who had received at least one dose of study drug. Between treatments, comparisons were made by logistic regression models adjusted for centre and baseline values of PASI scores. Odds ratios (ORs), 95% confidence intervals (CIs) and P-values were derived from these models. Patients with missing assessments were considered responders if they had already met the response criterion at the time of dropout for the primary end point and all other end points where response was investigated. Otherwise they were considered nonresponders. This method of imputation is referred to as the main method of imputation in the manuscript. Three sensitivity analyses were conducted: one analysing only patients who completed 24 weeks (as observed), one applying multiple imputation to replace missing values (Appendix S1) and one considering all patients with missing values as nonresponders (nonresponder imputation analysis).
Power calculation
With an assumed PASI 75 response rate of 85% for secukinumab and 60% for FAEs at week 24, 75 patients per treatment arm were considered sufficient to achieve a power of 90% to demonstrate superiority at a significance level of 0Á05. To account for some uncertainties in the underlying assumptions and to compensate for some expected dropouts and protocol violations, 100 patients per arm (200 in total) were planned to be randomized into this trial. The study was powered for the primary end point. The statistical analysis was not corrected for multiplicity. Therefore, all P-values and CIs for secondary end points are nominal and should be interpreted with caution.
Results
Patients
In total 105 patients were randomly assigned to secukinumab and 97 patients to FAEs. Two patients assigned to FAEs did not receive any study medication. All patients who received study medication were analysed for the primary outcome (full analysis set). Ninety-nine patients with secukinumab and 43 patients with FAEs completed the 24-week follow-up period of the study. For 99 patients with secukinumab and 48 patients with FAEs, data sufficiently close to week 24 were available for the analyses of this time point. Week 24 data for six patients treated with secukinumab and 47 patients treated with FAEs had to be imputed (Fig. 1) .
The baseline characteristics were similar in both groups, with a slightly higher baseline PASI and IGA mod 2011 in the secukinumab group and a slightly higher baseline DLQI in the FAE group (Table 1) . Around half (52Á5%) of all patients in this study had nail psoriasis symptoms at baseline. In these patients, the mean NAPSI was higher in the secukinumab group (31Á2) than in the FAE group (25Á9, Table 1 ). At week 24, the mean final study dose of FAE was 3Á3 AE 2Á2 highdose tablets per day.
The mean SF-36v2 component summary scales and domain scales were similar in both treatment groups at baseline (Table S1 ); see Supporting Information.
Efficacy
Secukinumab was superior to FAEs with respect to the primary end point of the study, with 89Á5% of patients in the secukinumab group and 33Á7% of patients in the FAE group achieving a PASI 75 response at week 24 (P < 0Á001). However, there is some uncertainty to this result, because of missing outcome data at week 24 that had to be imputed for 53 patients (six treated with secukinumab and 47 treated with FAEs). Therefore, sensitivity analyses were performed applying other methods of imputation to replace missing values. Despite higher efficacy rates achieved by FAEs, superiority of secukinumab was confirmed when applying multiple imputation (92Á0% vs. 47Á8% PASI 75 response, P < 0Á001) and analysing the data as observed without imputation: 92% (91 of 99 patients) vs. 50% (24 of 48 patients), P < 0Á001. Similar results to the main analysis were obtained with a nonresponder imputation; PASI 75 response rates at week 24 were 86Á7% with secukinumab vs. 25Á3% with FAEs (OR 19Á1, 95% CI 9Á2-39Á6; P < 0Á001; Appendix S1).
Applying the main method of imputation for the 53 patients with missing values, the proportion of patients achieving a PASI 90 response (clear or almost clear skin) at week 24 was greater with secukinumab (75%) than with FAEs (19Á0%) (P < 0Á001). This result was confirmed by nonresponder imputation (Appendix S1). Higher efficacy of secukinumab vs. FAEs was also observed for PASI 50, PASI 100 and IGA mod 2011 0/1 responses at week 24 applying the main method of imputation for 53 patients with missing values (Table 2 ). In patients with nail psoriasis at baseline, week 24 results were missing for seven patients treated with secukinumab and 22 patients treated with FAEs. Applying the main method of imputation for these patients, a greater proportion who were treated with secukinumab (67Á9%) achieved NAPSI 50 response compared with FAEs (18%) at week 24 (P < 0Á001).
Overall, secukinumab achieved higher PASI 50/75/90/100 and IGA mod 2011 0/1 responses vs. FAEs at each assessed time point throughout 24 weeks of treatment (Fig. 2) . The mean baseline DLQI scores were 17Á8 and 18Á5 for secukinumab and FAEs, respectively. At week 24 the adjusted mean changes for each group were À15Á0 and À7Á9, respectively (adjusted for baseline differences). The percentage of patients achieving a DLQI score of 0 or 1, indicating no impairment of health-related quality of life because of skin problems, was higher with secukinumab than with FAEs at each assessed time point through 24 weeks (week 24: 71Á4% vs. 25%, P < 0Á001; imputed values by main method for six patients treated with secukinumab and 47 patients treated with FAEs) (Fig. 2e, Table 2 ). The burden of treatment of psoriasis seemed to be a problem for fewer patients treated with secukinumab than with FAEs, as indicated by a post hoc analysis of question 10 of the DLQI at week 24 (Appendix S1).
For SF-36v2, minimally important differences for individual patients have been defined for each scale. 10 The percentage of patients achieving at least a minimal important improvement in the mental component summary scales of the SF-36v2 differed between treatment groups. More patients with secukinumab than with FAEs were found to achieve at least a minimally important improvement in domain scores for physical, bodily pain, general health, vitality, social functioning and mental health (Table 3) . FAEs with missing assessments at week 24 were considered responders if they had already met the response criterion at the time of dropout, otherwise they were considered nonresponders. b All CIs and P-values, with the exception of those for PASI 75 responders, are nominal and should be interpreted with caution. 
Safety
Compared with secukinumab, more patients with FAEs experienced diarrhoea, upper abdominal pain, flushing and lymphopenia (defined as any case where the investigator reported lymphopenia as an AE, Table 4 ). In total, 9Á5% of the patients treated with secukinumab and 41% of the patients treated with FAEs had their lowest lymphocyte count below the lower limit of normal; 1Á9% and 17% of patients had their lowest lymphocyte count 0Á5-0Á7 9 10 9 cells L À1 ; and 0% vs. 2% of patients had their lowest lymphocyte count < 0Á5 9 10 9 cells L À1 , respectively. Infections and infestations occurred in 62Á9% of patients with secukinumab and 54% of patients with FAEs (P = 0Á19). Overall, 5Á7% of patients (n = 6) with secukinumab and no patients with FAEs experienced Candida infections. Two patients experienced oral candidiasis, one had oral Percentage of all patients in the analysis, including patients with observed values and imputed values. *Number of patients with observed values and imputed values. The imputation was conducted as follows: patients with missing assessments were considered responders if they had already met the response criterion at the time of dropout, otherwise they were considered nonresponders. Secu, secukinumab; FAE, fumaric acid ester. and genital candidiasis, two had skin candidiasis and one reported an unspecified Candida infection. All occurrences were mild or moderate and none led to study drug discontinuation.
No deaths occurred during the study. Fewer patients with secukinumab (1Á9%, n = 2) than with FAEs (40%, n = 38) discontinued study treatment with an AE involved (any AE leading to discontinuation as opposed to primary reason for discontinuation; P < 0Á001). The most frequent AEs leading to discontinuation were related to the gastrointestinal tract, such as abdominal pain and diarrhoea (14 in the FAE group, none in the secukinumab group) and lymphopenia (11 in the FAE group and none in the secukinumab group). Four patients treated with FAEs experienced serious AEs. One patient underwent surgery for a pilonidal cyst, two were hospitalized for worsening of psoriasis and one was hospitalized for diarrhoea. Four patients with secukinumab experienced serious AEs. One patient underwent surgery for a clavicular fracture caused by a skiing accident. One patient was hospitalized for weakness and dehydration, which resolved after rehydration. A 72-year-old patient experienced a deep vein thrombosis from which he recovered after anticoagulation treatment. One patient experienced headaches and was diagnosed with brain metastases of a small cell lung cancer. Except for the case of hospitalization for diarrhoea in the FAE group, causal relationships with the study drug were not suspected for the serious AEs that occurred in this study.
Discussion
To our knowledge, PRIME is the first study to compare secukinumab with a nonbiological systemic treatment in a population of systemic-naive patients with moderate-to-severe plaque psoriasis. The population of this study was similar to that of other recent clinical trials in moderate-to-severe plaque psoriasis with respect to baseline characteristics, despite the fact that only systemic treatment-naive patients with a DLQI > 10 were eligible, with the notable difference of fewer than usual patients with psoriatic arthritis. 6, 11, 12 This was due to FAEs All patients in the analysis, including completers and dropouts. Up to 10 patients treated with secukinumab and up to 51 treated with fumaric acid esters (FAEs) with missing assessments were considered responders if they had already met the response criterion at the time of dropout, otherwise they were considered nonresponders. b All confidence intervals (CIs) and P-values are nominal and should be interpreted with caution. AEs occurring in > 10% of the study population are listed. FAE, fumaric acid ester; RR, relative risk; CI, confidence interval. a All discontinuations that were related to AEs. Six discontinuations in the FAE arm were related to AEs, but AEs were not the primary reasons for discontinuation in these six patients. AEs were the primary reasons for discontinuations in 32 patients in the FAE arm. b All patients in the analysis, including completers and dropouts; values are n (%). c All CIs and P-values are nominal and should be interpreted with caution.
not being indicated for psoriatic arthritis. The mean time since psoriasis diagnosis of > 16 years, along with the mean PASI of approximately 19 and the mean DLQI of approximately 18 at baseline, indicate a high disease burden in these patients, which is also reflected by the baseline results of the SF-36v2 questionnaire. The PRIME study demonstrates that secukinumab has greater efficacy than FAEs in achieving a PASI 75 response at week 24, which was the primary end point of the study. A PASI 90 response, representing clear or almost clear skin, and defined as a treatment goal by the European Medicines Agency for moderate-to-severe plaque psoriasis, 13 was achieved by 75%
and 19% of patients with secukinumab and FAEs, respectively.
In terms of quality of life, DLQI 0/1 responses were higher in secukinumab-treated patients vs. those receiving FAEs, indicating that this particular treatment goal can now be achieved in the majority of systemic treatment-naive patients using secukinumab as a first-line treatment for moderate-to-severe plaque psoriasis. This direct head-to-head study included approved and recommended psoriasis treatment options in Germany. Aside from differences in efficacy and safety, cost differences may also influence the selection of first-line treatments for psoriasis in clinical practice.
The high discontinuation rate in the FAE group is comparable with results from other clinical trials, both blinded and open label. [14] [15] [16] Patients with missing assessments (six treated with secukinumab and 47 treated with FAEs at week 24) were considered responders if they had met the response criterion already at the time of dropout. Otherwise they were considered as nonresponders. Due to the high discontinuation rate, there is some uncertainty with regard to the results, especially in the FAE treatment arm. Therefore, multiple imputation, analysis as observed and nonresponder imputation were also used as sensitivity analyses. While resulting in slightly different results for secukinumab and more strongly varying results for FAEs, all analyses confirmed a statistically significant difference between the treatments with regard to PASI 75 response. The open-label design of the study was necessary to allow adherence to the local product information of FAEs with respect to dose adjustments. This was a prerequisite for acceptance of the study results in the German health technology assessment process. A blinded assessor at each site assessed all objective measures of disease activity in order to reduce bias.
No new safety findings were observed for secukinumab in the PRIME study. Moreover, pooled long-term safety data have recently confirmed the favourable safety profile of secukinumab. 17 There were few serious AEs in either of the treatment groups. More patients discontinued FAEs due to AEs compared with patients on secukinumab. The AEs leading to discontinuation of FAEs were mostly related to gastrointestinal tolerability and lymphopenia, as would be expected based on the known safety profile of FAEs. 18 The main limitations of this study are its required openlabel design and the high discontinuation rate in the FAE arm, which may have reduced the statistical power of the study. The relatively short study duration is also a limitation, as longer-term data have previously shown that the efficacy of FAEs may increase further after week 24. 16 However, a period of 24 weeks is a suitable treatment period for a chronic disease according to the Institute for Quality and Efficiency in Healthcare. 19 Another limitation is that the study was powered only for the primary end point and that there were no corrections for multiplicity. Therefore, all other P-values and CIs are nominal and should be interpreted with caution. A final limitation is that the study was neither designed nor powered to detect differences in rare but important AEs.
The results from the PRIME study add to the body of evidence around intereukin-17A inhibition by demonstrating superior efficacy, quality of life and tolerability for secukinumab compared with FAEs in systemic treatment-naive patients with moderate-to-severe plaque psoriasis. 6, 10 
